Evercyte

Regina Grillari at EUROTOX 2017

Sept 10-13, 2017, Slovak National Theatre, Bratislava (Slovakia)

The 53rd Congress of the European Societies of Toxicology is to be held in Bratislava with over 30 symposia and workshops that will highlight the novel findings in the field of toxicology. Meet Regina Grillari on Sunday when she gives her talk  on the "Immortalization of Human Cells" - and see how Evercyte's products and services can assist your business!

Read more and get the programme 

Regina Grillari at Cell Culture Days 2017 

May 31– June 1, 2017, Center of Medical Research, Graz (Austria)

The Austrian Society for Cytometry (OEGfZ) organizes together with the Division of Biomedical Research the Cell Culture Days 2017.
The 2 day program includes lectures as well as workshops. Lectures will present the topics: 3D cell culture, regenerative medicine, tissue engineering and immune cells whereas workshops themes will include: bioreactors and biomaterials, tissue engineering, immortalization, immune cells, organoids and spheroid immunostaining.

Evercyte at highly respected Society of Toxicology meeting, ToxExpo 2017

Meet Johannes Grillari at ToxExpo 2017, in Baltimore from March 12-17th at booth 2566

Evercyte will be featuring a range of new offers and recently introduced services based on its capability to produce high quality cells that comply with Good Cell Culture Practice (GCCP) standards.

Available products and services now include

s A human podocyte cell line immortalized by telomerase that provides an important kidney toxicology model to complement Evercyte’s existing successful proximal tubular cell line RPTEC/TERT1 for kidney toxicity studies in vitro
s Human bronchial epithelial cells (HBEC3-KT) immortalized by telomerase that use well differentiated cells as model systems to study lung disease / cancer and toxicology
s Gene editing of human primary like cells using CrispR/Cas9 and RPTEC/TERT1 cells as an example that can be extended to any gene deletion, gene or reporter insertion
s Capability to generate induced pluripotent stem cells (iPSCs) from human urine in a fully non-invasive way 

Evercyte shares key cell NextGen data with Human Protein Atlas and clients

Vienna, 2-2017: Over the past two months, Evercyte researchers have contributed transcriptome analysis on several relevant human immortalized cell lines into HPA. This co-operation with the Swedish-based Atlas project has also provided important new insights into the next generation sequencing (NGS) data of Evercyte cell lines. NGS data of ell lines, like renal proximal tubular epithelial cells (RPTEC/TERT1), an important model for assessing kidney function and toxicology, umbilical vein endothelial cells (HUVEC/TERT2), a premier model for cardiovascular research, myoblasts (LHCN-M2) for muscle and sarcopenia research, adipose derived mesenchymal stem cells (ASC/TERT1) for the fields of adipogenesis, chondrogenesis and osteogenesis as well as corneal epithelial cells (hTCEpi) for eye research.

This means Evercyte is now able to offer download of NGS transcriptome data on hTERT immortalized and telomerased cell lines from our website, potentially enabling functionality and quality to be further enhanced.

Are you interested? Read more or get data directly after log in in our webshop. 
 

Evercyte is part of 'in3'

An integrated interdisciplinary approach to animal-free nanomaterial and chemical safety assessment.


Vienna, Innsbruck, 2-2017: The in3 project (grant no. 721975) is a Marie Curie Innovative Training Network that aims to drive the synergistic development and utilisation of in vitro and in silico tools for human chemical and nanomaterial (NM) safety assessment. The project will focus on differentiation of human induced Pluripotent Stem Cells (hiPSC) to toxicologically relevant target tissues including; brain, lung, liver and kidney. The tissues, from the same genetic backgrounds, will be exposed to several compounds and the data generated will be used to develop safety assessment approaches by integrating cheminformatics, mechanistic toxicology and biokinetics into computational models. The project will hire 15 PhD students to carry out these activities in a coordinated and highly collaborative fashion. The scientists trained within in3 will acquire a unique multidisciplinary skill set giving them a competitive employment advantage in safety assessment sciences, either in industry, governmental bodies or academia.

15 international phD postitions advertised

Paul Jennings, Medizinische Universität Innsbruck and speaker of the in3 consortium announces, that the project will run from January 2017 to the end of 2021. Recruitment is open now and will remain open until all positions are filled. Each of the 15 positions advertised is a 3 year PhD position. Applicants must be Early-Stage Researchers (ESRs), meaning that they are within the first four years (full-time equivalent) of their research careers and have not yet been awarded a doctoral degree (PhD). We expect the first ESRs to commence employment in March 2017. We aim to have all positions filled by July 2017.

For more information please visit http://estiv.org/in3
 

Evercyte announces 2 days training course on kidney-toxicity in the framework of CAAT Academy

Vienna, 07-2016: Evercyte will host and co-organize an intense 2 days "hand-on" training course "Kidney toxicity & best practices". This course is part of a series of workshops initiated by the CAAT Academy (Center for Alternatives to Animal Testing - a joint venture between University of Konstanz and Johns Hopkins University) in order to train toxicologists in relevant alternative methods and to bring experts together. It will take place on September 22-23, 2016 in Vienna and will comprise a series of lectures and hands-on trainings held by experts in the field.
 

Evercyte's renal proximal tubular epithelial cell line 'RPTEC/TERT1' combines the functionality of primary cells with indefinite growth charateristics under defined culture conditions.

Are you looking for a cell line which is a predictive model to study kidney metabolismfibrosis or cancerin vitro or a highly relevant model for pre-clinical toxicity tests and much more applictions? Our RPTEC/TERT1 cell line might be just the perfect choice!

you want to get more information on our cells?
join our mailinglist

Evercyte and VTU Technology collaborate on development of recombinant media supplements

Vienna / Grambach, 05-2016: Evercyte GmbH, the leading provider of immortalized human primary-like cells and VTU Technology, the globally acting protein expression expert announce that they have entered into a collaboration agreement on the development of recombinant media supplements for cell culture applications. The first conjointly developed recombinant product – Vascular Endothelial Growth Factor 165 (VEGF 165) has been recently launched with further targets in the pipeline.

read more 
more about our product